Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

about

Targeting BCL-2 regulated apoptosis in cancer.miR-216a-5p inhibits malignant progression in small cell lung cancer: involvement of the Bcl-2 family proteins BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer

P2860

Q53819035-20870963-499F-4271-9182-79179597348D Q58694717-D222E76A-3F46-4E0A-BE9D-45BA11C15945 Q58779838-B4041C8C-CED2-49A3-8828-12E5148F2C99

P2860

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

Item

http://www.wikidata.org/entity/Q45072361

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@en

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@nl

type

Item

label

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@en

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@nl

prefLabel

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@en

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@nl

P1476

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

@en

P2093

Andrew J Souers

http://www.w3.org/2001/XMLSchema#string

Anthony C Faber

http://www.w3.org/2001/XMLSchema#string

Carlotta Costa

http://www.w3.org/2001/XMLSchema#string

Cyril H Benes

http://www.w3.org/2001/XMLSchema#string

Geoffrey W Krystal

http://www.w3.org/2001/XMLSchema#string

Giovanna T Stein

http://www.w3.org/2001/XMLSchema#string

Hisashi Harada

http://www.w3.org/2001/XMLSchema#string

Joel D Leverson

http://www.w3.org/2001/XMLSchema#string

Krista M Powell

http://www.w3.org/2001/XMLSchema#string

Laura R Saunders

http://www.w3.org/2001/XMLSchema#string

P2860

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Systematic identification of genomic markers of drug sensitivity in cancer cells

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

Programmed anuclear cell death delimits platelet life span.

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

P304

360-369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-1606

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Konstantinos V Floros

Timothy L Lochmann

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29118061

http://www.w3.org/2001/XMLSchema#string

P932

5771805

http://www.w3.org/2001/XMLSchema#string

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

about

P2860

P2860

Venetoclax is effective in small cell lung cancers with high BCL-2 expression.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932